Page 91 - Read Online

Toniutto et al. Hepatoma Res 2020;6:50 I http://dx.doi.org/10.20517/2394-5079.2020.40 Page 21 of 21

transplantation in patients with hepatocellular carcinoma. Ann Transplant 2013;18:448-59.
133. Mangus RS, Fridell JA, Vianna RM, Cooper AB, Jones DT, et al. Use of the piggyback hepatectomy technique in liver transplant
recipients with hepatocellular carcinoma. Transplantation 2008;85:1496-9.
134. Khan S, Silva MA, Tan YM, John A, Gunson B, et al. Conventional versus piggyback technique of caval implantation; without extra-
corporeal veno-venous bypass. A comparative study. Transpl Int 2006;19:795-801.
135. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after
liver transplantation. Hepatology 2015;61:895-904.
136. van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, et al. Ischemia/reperfusion accelerates the outgrowth of
hepatic micrometastases in a highly standardized murine model. Hepatology 2005;42:165-75.
137. Man K, Ng KT, Lo CM, Ho JW, Sun BS, et al. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--
activation of cell invasion and migration pathways. Liver Transpl 2007;13:1669-77.
138. Ku Y, Kusunoki N, Shiotani M, Maeda I, Iwasaki T, et al. Stimulation of haematogenous liver metastases by ischaemia-reperfusion in
rats. Eur J Surg 1999;165:801-7.
139. Gasbarrini A, Addolorato G, Di Campli C, Simoncini M, Montemagno S, et al. Gender affects reperfusion injury in rat liver. Dig Dis Sci
2001;46:1305-12.
140. Burra P, De Martin E, Gitto S, Villa E. Influence of age and gender before and after liver transplantation. Liver Transpl 2013;19:122-34.
141. Brahimi-Horn MC, Pouyssegur J. Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol
2007;73:450-7.
142. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind
heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005;16:554-63.
143. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, et al. Incidence and risk factors of hepatocellular carcinoma recurrence after
liver transplantation in the MELD era. Dig Dis Sci 2012;57:806-12.
144. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, et al. Optimal utilization of donor grafts with extended criteria: a single-
center experience in over 1000 liver transplants. Ann Surg 2006;243:748-53; discussion 53-5.
145. Segev DL, Maley WR, Simpkins CE, Locke JE, Nguyen GC, et al. Minimizing risk associated with elderly liver donors by matching to
preferred recipients. Hepatology 2007;46:1907-18.
146. Tashiro H, Kuroda S, Mikuriya Y, Ohdan H. Ischemia-reperfusion injury in patients with fatty liver and the clinical impact of steatotic
liver on hepatic surgery. Surg Today 2014;44:1611-25.
147. Jimenez-Castro MB, Casillas-Ramirez A, Mendes-Braz M, Massip-Salcedo M, Gracia-Sancho J, et al. Adiponectin and resistin protect
steatotic livers undergoing transplantation. J Hepatol 2013;59:1208-14.
148. Mathur A, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, et al. Obesity portends increased morbidity and earlier recurrence
following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013;15:504-10.
149. Saxena NK, Sharma D, Ding X, Lin S, Marra F, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is
involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007;67:2497-507.
150. Rega G, Kaun C, Demyanets S, Pfaffenberger S, Rychli K, et al. Vascular endothelial growth factor is induced by the inflammatory
cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc
Biol 2007;27:1587-95.
151. Siegel AB, Lim EA, Wang S, Brubaker W, Rodriguez RD, et al. Diabetes, body mass index, and outcomes in hepatocellular carcinoma
patients undergoing liver transplantation. Transplantation 2012;94:539-43.
152. Martins PN, Pratschke J, Pascher A, Fritsche L, Frei U, et al. Age and immune response in organ transplantation. Transplantation
2005;79:127-32.
153. Watt KD. Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol 2015;12:639-48.
154. Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of
immunosuppression? Transl Gastroenterol Hepatol 2017;2:80.
155. Schnitzbauer AA, Schlitt HJ, Geissler EK. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after
liver transplantation: a gap between basic science and clinical evidence. Transplantation 2011;91:1173-6.
156. Liang W, Wang D, Ling X, Kao AA, Kong Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular
carcinoma: a meta-analysis. Liver Transpl 2012;18:62-9.
157. Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, et al. Sirolimus use in liver transplant recipients with hepatocellular
carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016;100:116-25.
158. Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of
hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014;27:1039-49.
159. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, et al. Liver transplantation for hepatocellular carcinoma under
calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008;248:857-62.
160. Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC, Pieri G, Garcia-Caparros C, et al. Reduced exposure to calcineurin inhibitors early
after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013;59:1193-9.
161. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006;6:1774-80.
162. Benitez C, Londono MC, Miquel R, Manzia TM, Abraldes JG, et al. Prospective multicenter clinical trial of immunosuppressive drug
withdrawal in stable adult liver transplant recipients. Hepatology 2013;58:1824-35.
163. Angelico R, Parente A, Manzia TM. Using a weaning immunosuppression protocol in liver transplantation recipients with hepatocellular
carcinoma: a compromise between the risk of recurrence and the risk of rejection? Transl Gastroenterol Hepatol 2017;2:74.